Silverarc Capital Management, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Silverarc Capital Management, LLC reported 66 stock positions worth $848.6 million. Its top holding was Kalvista Pharmaceuticals (KALV) at 6.8% of the portfolio, followed by Dianthus Therapeutics (DNTH, 6.5%) and Cogent Biosciences (COGT, 6.0%). Compared with Q4 2025, it opened 21 new positions, sold out of 18, added to 16 and reduced 27. The biggest buy was Erasca (ERAS, shares +41%) and the biggest sale Abivax SA-ADR (ABVX, shares −28%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $848.6M (Q1 2026)
- SEC Filing
- 0001420506-26-001011 ↗ filed May 14, 2026
Holdings Value
Holdings 66 stocks · $848.6M
| KALV Kalvista Pharmaceuticals Inc. | 6.82% | 2,876,407 | $57.9M | Add +18.5% |
| DNTH Dianthus Therapeutics Inc. | 6.47% | 654,746 | $54.9M | Reduce -12.7% |
| COGT Cogent Biosciences Inc. | 5.96% | 1,314,189 | $50.6M | Add +5.5% |
| CELC Celcuity Inc. | 4.81% | 357,903 | $40.9M | Reduce -4.6% |
| IMNM Immunome Inc. | 4.77% | 1,850,278 | $40.5M | Add +64.3% |
| KOD Kodiak Sciences Inc. | 4.46% | 991,930 | $37.8M | Reduce -3.0% |
| NUVL Nuvalent Inc. Class A | 4.28% | 354,914 | $36.4M | Add +14.0% |
| ABVX Abivax SA-ADR | 3.97% | 302,530 | $33.7M | Reduce -28.3% |
| GLUE Monte Rosa Therapeutics Inc. | 3.88% | 2,002,040 | $32.9M | Add +94.5% |
| ERAS Erasca Inc. | 3.53% | 1,851,812 | $30.0M | Add +40.5% |
| ASND Ascendis Pharma A/S | 3.36% | 124,658 | $28.5M | Add +153.2% |
| URGN Urogen Pharma Ltd. | 3.18% | 1,503,045 | $27.0M | Reduce -13.6% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.14% | 306,000 | $26.6M | Add +125.1% |
| PRAX Praxis Precision Medicines I | 2.72% | 71,552 | $23.1M | Reduce -13.2% |
| ZBIO Zenas Biopharma Inc. | 2.62% | 1,135,935 | $22.2M | New |
| SNDX Syndax Pharmaceuticals Inc. | 2.45% | 888,987 | $20.8M | Add +38.3% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.18% | 466,345 | $18.5M | Add +1.8% |
| SRRK Scholar Rock Holding Corp. | 1.97% | 339,613 | $16.7M | New |
| ALKS Alkermes PLC | 1.92% | 460,314 | $16.3M | New |
| ORIC Oric Pharmaceuticals Inc. | 1.64% | 1,100,010 | $13.9M | Reduce -1.5% |
| IRON Disc Medicine Inc. | 1.48% | 196,028 | $12.5M | New |
| HLXC Helix Acquisition Corp. Class A | 1.45% | 1,208,986 | $12.3M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.36% | 197,759 | $11.5M | New |
| CGON CG Oncology Inc. | 1.33% | 166,349 | $11.3M | Reduce -53.9% |
| IMVT Immunovant Inc. | 1.21% | 414,236 | $10.3M | New |
| SYRE Spyre Therapeutics Inc. | 1.11% | 186,618 | $9.4M | Reduce -0.6% |
| BIIB Biogen Inc. | 1.10% | 50,967 | $9.3M | Reduce -32.4% |
| GH Guardant Health Inc. | 1.07% | 98,514 | $9.1M | Add +7.2% |
| PCVX Vaxcyte Inc. | 0.99% | 144,981 | $8.4M | Reduce -2.6% |
| SVRA Savara Inc. | 0.92% | 1,430,982 | $7.8M | New |
| BNTC Benitec Biopharma Inc. | 0.90% | 717,725 | $7.6M | Reduce -1.9% |
| ORKA Oruka Therapeutics Inc. | 0.87% | 150,908 | $7.4M | New |
| CGEN Compugen Ltd. | 0.83% | 3,315,845 | $7.1M | Reduce -4.7% |
| TRVI Trevi Therapeutics Inc. | 0.72% | 511,127 | $6.1M | Reduce -5.6% |
| INSM Insmed Inc. | 0.69% | 35,850 | $5.9M | Reduce -49.7% |
| VCYT Veracyte Inc. | 0.68% | 179,700 | $5.8M | Reduce -49.7% |
| CERS Cerus Corp. | 0.68% | 3,176,547 | $5.8M | Add +12.9% |
| CLDX Celldex Therapeutics Inc. | 0.67% | 178,378 | $5.7M | Reduce -6.6% |
| CCCC C4 Therapeutics Inc. | 0.59% | 1,911,785 | $5.0M | Reduce -4.1% |
| CYTK Cytokinetics Inc. | 0.55% | 71,203 | $4.7M | New |
| CLYM Climb Bio Inc. | 0.55% | 684,908 | $4.7M | New |
| CMPX Compass Therapeutics Inc. | 0.54% | 859,049 | $4.5M | Reduce -18.3% |
| SRZN Surrozen Inc. | 0.50% | 144,255 | $4.2M | Reduce -8.3% |
| CTNM Contineum Therapeutics Inc. Class A | 0.46% | 301,729 | $3.9M | Reduce -1.9% |
| ZURA Zura Bio Ltd. | 0.39% | 560,651 | $3.3M | New |
| FULC Fulcrum Therapeutics Inc. | 0.38% | 419,949 | $3.2M | Add +6.4% |
| ABEO Abeona Therapeutics Inc. | 0.34% | 648,942 | $2.9M | Add +3.4% |
| CAMP CAMP4 Therapeutics Corp. | 0.34% | 653,594 | $2.9M | New |
| ANNX Annexon Inc. | 0.32% | 496,461 | $2.8M | New |
| ELUT Elutia Inc. | 0.31% | 2,498,020 | $2.6M | Reduce -9.2% |
| CBIO Crescent Biopharma Inc. | 0.28% | 130,500 | $2.4M | New |
| MNPR Monopar Therapeutics Inc. | 0.28% | 43,488 | $2.4M | New |
| OVID Ovid Therapeutics Inc. | 0.26% | 1,000,000 | $2.2M | New |
| NXTC Nextcure Inc. | 0.22% | 176,057 | $1.9M | No change |
| CMPS Compass Pathways PLC | 0.20% | 300,000 | $1.7M | New |
| NMRA Neumora Therapeutics Inc. | 0.19% | 818,156 | $1.6M | New |
| SION Sionna Therapeutics Inc. | 0.19% | 39,417 | $1.6M | Reduce -4.9% |
| TELA Tela Bio Inc. | 0.17% | 2,259,312 | $1.4M | Reduce -14.7% |
| EWTX Edgewise Therapeutics Inc. | 0.16% | 42,615 | $1.3M | Add +1.3% |
| REPL Replimune Group Inc. | 0.15% | 171,936 | $1.3M | New |
| GENB Generate Biomedicines Inc. | 0.15% | 100,000 | $1.3M | New |
| RADX Radiopharm Theranostics Ltd. | 0.10% | 187,406 | $806K | No change |
| GUTS Fractyl Health Inc. | 0.09% | 1,701,625 | $779K | Reduce -82.7% |
| IBIO Ibio Inc. | 0.05% | 226,000 | $429K | Add +113.2% |
| ADGM Adagio Medical Holdings Inc. | 0.03% | 251,972 | $290K | Reduce -51.1% |
| AARD Aardvark Therapeutics Inc. | 0.01% | 33,684 | $127K | Reduce -88.9% |
Options reported separately and not counted above: SPDR SERIES TRUST puts ($105.4M), UNIQURE NV calls ($8.2M), SYNDAX PHARMACEUTICALS INC calls ($7.5M), CELCUITY INC calls ($6.2M), FULCRUM THERAPEUTICS INC calls ($3.0M), COMPASS THERAPEUTICS INC calls ($912K).
Other holdings (1): bonds, preferreds, convertibles and warrants · $2K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $2K | No change |
Total filed on the 13F, all lines: $848.6M.
Portfolio Sells Q4 2025 → Q1 2026
| ABVX Abivax SA-ADR | Reduce -28.3% | 3.97% | −4.27 |
| GUTS Fractyl Health Inc. | Reduce -82.7% | 0.09% | −3.04 |
| URGN Urogen Pharma Ltd. | Reduce -13.6% | 3.18% | −2.71 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −1.57 |
| PFE Pfizer Inc. | Sold out | 0.00% | −1.51 |
| VCYT Veracyte Inc. | Reduce -49.7% | 0.68% | −1.50 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −1.38 |
| INSM Insmed Inc. | Reduce -49.7% | 0.69% | −1.10 |
| GOSS Gossamer Bio Inc. | Sold out | 0.00% | −0.96 |
| LXEO Lexeo Therapeutics Inc. | Sold out | 0.00% | −0.89 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.88 |
| CGON CG Oncology Inc. | Reduce -53.9% | 1.33% | −0.84 |
| BIIB Biogen Inc. | Reduce -32.4% | 1.10% | −0.82 |
| PRAX Praxis Precision Medicines I | Reduce -13.2% | 2.72% | −0.80 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.79 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −0.75 |
| CELC Celcuity Inc. | Reduce -4.6% | 4.81% | −0.60 |
| AARD Aardvark Therapeutics Inc. | Reduce -88.9% | 0.01% | −0.56 |
| BNTC Benitec Biopharma Inc. | Reduce -1.9% | 0.90% | −0.53 |
| MLYS Mineralys Therapeutics Inc. | Sold out | 0.00% | −0.50 |
| RLAY Relay Therapeutics Inc. | Sold out | 0.00% | −0.49 |
| QURE Uniqure NV | Sold out | 0.00% | −0.44 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −0.43 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −0.39 |
| TELA Tela Bio Inc. | Reduce -14.7% | 0.17% | −0.29 |
| CMPX Compass Therapeutics Inc. | Reduce -18.3% | 0.54% | −0.28 |
| TRVI Trevi Therapeutics Inc. | Reduce -5.6% | 0.72% | −0.26 |
| CTMX Cytomx Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| XFOR X4 Pharmaceuticals Inc. | Sold out | 0.00% | −0.21 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −0.11 |
| CLDX Celldex Therapeutics Inc. | Reduce -6.6% | 0.67% | −0.08 |
| SION Sionna Therapeutics Inc. | Reduce -4.9% | 0.19% | −0.06 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -1.9% | 0.46% | −0.04 |
| ADGM Adagio Medical Holdings Inc. | Reduce -51.1% | 0.03% | −0.04 |
| RAPP Rapport Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| PALI Palisade Bio Inc. | Sold out | 0.00% | −0.03 |
| SRZN Surrozen Inc. | Reduce -8.3% | 0.50% | −0.02 |
| PCVX Vaxcyte Inc. | Reduce -2.6% | 0.99% | −0.00 |
| ELUT Elutia Inc. | Reduce -9.2% | 0.31% | +0.03 |
| CCCC C4 Therapeutics Inc. | Reduce -4.1% | 0.59% | +0.04 |
| CGEN Compugen Ltd. | Reduce -4.7% | 0.83% | +0.06 |
| SYRE Spyre Therapeutics Inc. | Reduce -0.6% | 1.11% | +0.22 |
| KOD Kodiak Sciences Inc. | Reduce -3.0% | 4.46% | +0.32 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -1.5% | 1.64% | +0.32 |
| DNTH Dianthus Therapeutics Inc. | Reduce -12.7% | 6.47% | +2.00 |
Portfolio Buys Q4 2025 → Q1 2026
| ERAS Erasca Inc. | Add +40.5% | 3.53% | +2.82 |
| ZBIO Zenas Biopharma Inc. | New | 2.62% | +2.62 |
| SRRK Scholar Rock Holding Corp. | New | 1.97% | +1.97 |
| ALKS Alkermes PLC | New | 1.92% | +1.92 |
| ASND Ascendis Pharma A/S | Add +153.2% | 3.36% | +1.84 |
| GLUE Monte Rosa Therapeutics Inc. | Add +94.5% | 3.88% | +1.55 |
| IRON Disc Medicine Inc. | New | 1.48% | +1.48 |
| HLXC Helix Acquisition Corp. Class A | New | 1.45% | +1.45 |
| XENE Xenon Pharmaceuticals Inc. | New | 1.36% | +1.36 |
| IMNM Immunome Inc. | Add +64.3% | 4.77% | +1.27 |
| IMVT Immunovant Inc. | New | 1.21% | +1.21 |
| KALV Kalvista Pharmaceuticals Inc. | Add +18.5% | 6.82% | +1.15 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +125.1% | 3.14% | +1.03 |
| SVRA Savara Inc. | New | 0.92% | +0.92 |
| ORKA Oruka Therapeutics Inc. | New | 0.87% | +0.87 |
| CYTK Cytokinetics Inc. | New | 0.55% | +0.55 |
| CLYM Climb Bio Inc. | New | 0.55% | +0.55 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +1.8% | 2.18% | +0.52 |
| SNDX Syndax Pharmaceuticals Inc. | Add +38.3% | 2.45% | +0.49 |
| ZURA Zura Bio Ltd. | New | 0.39% | +0.39 |
| CAMP CAMP4 Therapeutics Corp. | New | 0.34% | +0.34 |
| ANNX Annexon Inc. | New | 0.32% | +0.32 |
| CBIO Crescent Biopharma Inc. | New | 0.28% | +0.28 |
| MNPR Monopar Therapeutics Inc. | New | 0.28% | +0.28 |
| OVID Ovid Therapeutics Inc. | New | 0.26% | +0.26 |
| CMPS Compass Pathways PLC | New | 0.20% | +0.20 |
| NMRA Neumora Therapeutics Inc. | New | 0.19% | +0.19 |
| REPL Replimune Group Inc. | New | 0.15% | +0.15 |
| GENB Generate Biomedicines Inc. | New | 0.15% | +0.15 |
| IBIO Ibio Inc. | Add +113.2% | 0.05% | +0.02 |
| EWTX Edgewise Therapeutics Inc. | Add +1.3% | 0.16% | +0.01 |
| ABEO Abeona Therapeutics Inc. | Add +3.4% | 0.34% | −0.14 |
| CERS Cerus Corp. | Add +12.9% | 0.68% | −0.16 |
| NUVL Nuvalent Inc. Class A | Add +14.0% | 4.28% | −0.25 |
| FULC Fulcrum Therapeutics Inc. | Add +6.4% | 0.38% | −0.27 |
| GH Guardant Health Inc. | Add +7.2% | 1.07% | −0.29 |
| COGT Cogent Biosciences Inc. | Add +5.5% | 5.96% | −0.44 |
Options Activity Q4 2025 → Q1 2026
| SPDR SERIES TRUST | put | New | 825,000 | $105.4M |
| UNIQURE NV | call | Reduce -30.6% | 500,000 | $8.2M |
| SYNDAX PHARMACEUTICALS INC | call | New | 320,000 | $7.5M |
| CELCUITY INC | call | New | 54,500 | $6.2M |
| KALVISTA PHARMACEUTICALS INC | call | Sold out | 290,600 | $4.7Mbefore exit |
| ULTRAGENYX PHARMACEUTICAL IN | call | Sold out | 110,000 | $2.5Mbefore exit |
| COMPASS THERAPEUTICS INC | call | New | 172,400 | $912K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |